• Corpus ID: 29905234

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

  title={Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?},
  author={Ethan B. Russo},
  journal={Neuro endocrinology letters},
  volume={25 1-2},
  • Ethan B. Russo
  • Published 2004
  • Medicine, Biology
  • Neuro endocrinology letters
OBJECTIVES This study examines the concept of clinical endocannabinoid deficiency (CECD), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis. METHODS Available literature was reviewed, and literature searches pursued via the National Library of Medicine database and other resources. RESULTS Migraine has numerous relationships to endocannabinoid function. Anandamide… 

Emerging pharmacological strategies for the treatment of fibromyalgia

Investigation of a range of novel targets, such as melatoninergic, cannabinoid, dopamine, NMDA, angiotensin, orexin and opioid receptors, and ion channels has provided efficacy outcomes that improve the health status of patients with FM.

Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine

The interaction of the endocannabinoid and kynurenine system has been demonstrated to be therapeutically relevant in a number of pathological conditions, such as cannabis addiction, psychosis, schizophrenia and epilepsy.

Cannabinoids in the management of diffi cult to treat pain

This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing canna- binoids in pain

The Endocannabinoid System: An Osteopathic Perspective

  • J. McPartland
  • Medicine, Biology
    The Journal of the American Osteopathic Association
  • 2008
A new model to describe reciprocal interactions between somatic dysfunction and the endocannabinoid system is proposed and has broad therapeutic potential, including the treatment of patients with somatics dysfunction, chronic pain, and neurodegenerative diseases as well as inflammatory conditions, bowel dysfunctions, and psychological disorders.

Cannabinoids in the management of difficult to treat pain

Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles, and their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise.

The endocannabinoid system and migraine

Neoteric pharmacotherapeutic targets in fibromyalgia

Current research on novel sedative–hypnotics, anti-epileptic medications, various reuptake inhibitors, growth hormone agonists, canabinoid agonists), non-opiate analgesics and 5-HT3 antagonists offers hope for the next generation of therapeutic options for fibromyalgia.

Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis)

There is insufficient evidence for recommendation for any cannabinoid preparations for symptom management in patients with chronic pain associated with rheumatic diseases, and cannabinoids were generally well tolerated despite some troublesome side effects and safe during the study duration.

The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome

The role of the endocannabinoid system in gastrointestinal physiology is discussed and the involvement of this system in the context of symptoms associated with IBS is considered and a possible role is considered in the pathophysiology and treatment of IBS.



Cannabinoids and Cystic Fibrosis: A Novel Approach to Etiology and Therapy

It is proposed here for the first time, to administer THC to Cystic Fibrosis patients, hoping that the cannabinoid will alleviate malnutrition and thus help prevent wasting in CF patients and by elevating these levels, symptoms may improve.

Cannabinoids for gastrointestinal diseases: potential therapeutic applications

  • G. CarloA. Izzo
  • Medicine, Biology
    Expert opinion on investigational drugs
  • 2003
A pharmacological modulation of the endogenous cannabinoid system could provide new therapeutics for the treatment of a number of gastrointestinal diseases, including nausea and vomiting, gastric ulcers, irritable bowel syndrome, Crohn’s disease, secretory diarrhoea, paralytic ileus and gastroesophageal reflux disease.

Negative modultors of excitatory amino acids in episodic and chronic migraine: preventing and reverting chronic migraine. Special lecture 7th INWIN Congress.

The mechanism capable of transforming episodic migraine into chronic migraine is attributed by the authors to hyperalgesia and related neuroplastic changes, chiefly long-term potentiation, due to the

Fibromyalgia and headache. Failure of serotonergic analgesia and N-methyl-D-aspartate-mediated neuronal plasticity: their common clues.

Empirical data is analysed supporting the hypothesis that analgesic disruption and a consequent hyperalgesic state are mechanisms of both migraine and fibromyalgia and suggest that migraine may represent a risk factor for fibromy arthritis.

Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy.

The combination of MAOIs with 5-HTP significantly improved fibromyalgia syndrome as determined by Visual Analogic Scale whereas the other treatments yielded poorer benefits.

Evaluation of drug treatment in irritable bowel syndrome.

  • N. Talley
  • Medicine
    British journal of clinical pharmacology
  • 2003
A meta-analysis concluded that the tricyclic antidepressants were superior to placebo in IBS, although the individual trial results were variable, and additional efficacious therapeutic options for patients with IBS will soon emerge.

The Pharmacology of Current Anti‐Migraine Drugs

It is found that acute anti-migraine agents (e.g., ergots, sumatriptan) share high affinity for 5-HT1D receptors, which appears to be present in certain intracranial blood vessels and may mediate neuronal depolarizations at the cellular level.

Cannabinoids in pain management

  • E. Russo
  • Medicine
    BMJ : British Medical Journal
  • 2001
The authors chose to broaden the alleged impact of their limited investigation to relegate the use of cannabis and cannabinoids to a back seat in future analgesic applications, and this contention is not supported by their limited data.

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

Cannabis medicinal extracts can improve neurogenic symptoms unresponsive to standard treatments, and unwanted effects are predictable and generally well tolerated.